H
Hangzhou SynRx Therapeutics
Delivering the first-in-class medicines to cancer patients
About Hangzhou SynRx Therapeutics
Hangzhou SynRx Therapeutics, founded in 2021 by Professor Xiaochun Yu and Song Liu, is a biopharmaceutical company operating in the oncology sector. The firm is strategically located in Hangzhou, China, with a research and development branch in Shanghai. SynRx focuses on creating targeted cancer therapies by leveraging the concept of synthetic lethality. This approach targets inherent weaknesses in cancer cells, specifically defects in their DNA damage repair (DDR) pathways, to induce cell death while leaving healthy cells unharmed.
The company was founded based on the original research of Professor Yu, who serves as the company's chairman. He is a Professor and the Associate Dean of the School of Life Sciences at Westlake University and also holds a professorship at the University of Michigan Medical School. His extensive background in the field, including publishing over 100 academic papers, forms the scientific foundation of the company. Song Liu holds the position of CEO. In November 2022, the company secured $14.2 million in a seed funding round from investors including the National Small and Medium-sized Enterprise Development Fund, Zhejiang Haibang Investment Management, and ihubo.
SynRx's business model is centered on the research, development, and eventual commercialization of novel anti-tumor drugs. The company's revenue generation will likely depend on achieving clinical milestones, securing further investment, and forming partnerships with larger pharmaceutical companies for late-stage development and commercialization. Its primary clients are in the medical and pharmaceutical industries. The company's product pipeline is currently in the preclinical stage and includes several first-in-class compounds. These include SY001 and SY002, which target solid tumors with homologous recombination repair deficiencies, and SY003 for other solid tumors. More specifically, their research has led to the development of inhibitors for DNA polymerase θ (POLθ) and poly(ADP-ribose) glycohydrolase (PARG), such as SYX-3759, for treating cancers like triple-negative breast cancer.
The core of SynRx's strategy is synthetic lethality, a precision medicine technique that exploits the genetic vulnerabilities of cancer cells. It works on the principle that while a single gene mutation might not be fatal to a cell, a combination of mutations or the inhibition of a second, related gene can lead to cell death. This allows for the development of therapies that are highly specific to cancer cells, which often have mutations in tumor suppressor genes, thereby offering a potentially wider therapeutic window with fewer side effects compared to conventional chemotherapy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 24.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Nov 2022 | $14M | $55M | Longpan Investment · Hangzhou Xihu District Kechuang Equity Investment · Haibang Capital · Ritual Medicine | ↗ |
Growth signals
Latest recorded traffic for Hangzhou SynRx Therapeutics is 240 monthly website visits, down 36.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hangzhou SynRx Therapeutics in its local ecosystem
The Hangzhou SynRx Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- LILongpan Investment
- HIHangzhou Xihu District Kechuang Equity Investment
- HCHaibang Capital
- RMRitual Medicine
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hangzhou SynRx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hangzhou SynRx Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










